• 1
    Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002;47:83343.
  • 2
    Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50(13 Suppl 1):7S57S.
  • 3
    Odegard O. Fertility of psychiatric first admissions in Norway 1936–1975. Acta Psychiatr Scand 1980;62:21220.
  • 4
    Miller LJ. Comprehensive care of pregnant mentally ill women. J Ment Health Adm 1992;19:1707.
  • 5
    Bundy H, Stahl D, MacCabe JH. A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. Acta Psychiatr Scand 2011;123:98106.
  • 6
    Vigod SN, Seeman MV, Ray JG, Anderson GM, Dennis CL, Grigoriadis S, et al. Temporal trends in general and age-specific fertility rates among women with schizophrenia (1996–2009): a population-based study in Ontario, Canada. Schizophr Res 2012;139:16975.
  • 7
    Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005;162:7991.
  • 8
    Bennedsen BE. Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophr Res 1998;33:126.
  • 9
    Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. Br J Psychiatry 1999;175:23945.
  • 10
    Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet 2011;283:1417.
  • 11
    Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies. Psychol Med 1996;26:27987.
  • 12
    Dewa CS, Goering P. Lessons learned from trends in psychotropic drug expenditures in a canadian province. Psychiatr Serv 2001;52:12457.
  • 13
    Joseph KS, Fahey J. Validation of perinatal data in the Discharge Abstract Database of the Canadian Institute for Health Information. Chronic Dis Can 2009;29:96100.
  • 14
    Joseph KS, Liu S, Rouleau J, Kirby RS, Kramer MS, Sauve R, et al. Severe maternal morbidity in Canada, 2003 to 2007: surveillance using routine hospitalization data and ICD-10CA codes. J Obstet Gynaecol Can 2010;32:83746.
  • 15
    Williams JI, O'Brien BJ, Sellors C, Grootendorst P, Willison D. A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, Blacksterin-Hirsch P, Fooks C, Naylor CD editors. Patterns of Health Care in Ontario The ICES Practice Atlas. Ottawa: Canadian Medical Association; 1996. pp 33945.
  • 16
    Becker T, Hux J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care 2011;34:398402.
  • 17
    Martens PJFR, McKeen N, The Need to Know Team, Burland E, Jebamani L, Burchill C, De Coster C, Ekuma O, Prior H, Chateau D, Robinson R, Metge C. Patterns of Regional Mental Illness Disorder Diagnoses and Service Use in Manitoba: A Population-Based Study. Winnipeg, MB: Manitoba Centre for Health Policy, 2004.
  • 18
    Health Canada. Perinatal Health Indicators for Canada: A Resource Manual. Ottawa, Canada: Minister of Public Works and Government Services Canada; 2000.
  • 19
    Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry 2010;22:47284.
  • 20
    McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:1932.
  • 21
    Yanit KE, Snowden JM, Cheng YW, Caughey AB. The impact of chronic hypertension and pregestational diabetes on pregnancy outcomes. Am J Obstet Gynecol 2012;207:333.e16.
  • 22
    Ray JG, Sgro M, Mamdani MM, Glazier RH, Bocking A, Hilliard R, et al. Birth weight curves tailored to maternal world region. J Obstet Gynaecol Can 2012;34:15971.
  • 23
    Urquia ML, Frank JW, Glazier RH, Moineddin R. Birth outcomes by neighbourhood income and recent immigration in Toronto. Health Rep 2007;18:2130.
  • 24
    Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:51216.
  • 25
    Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, et al. Validation of a case definition to define hypertension using administrative data. Hypertension 2009;54:14238.
  • 26
    Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB, Frydenberg M. Obstetric complications in women with schizophrenia. Schizophr Res 2001;47:16775.
  • 27
    Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010;341:c4245.
  • 28
    Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM. Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res 2002;58:2219.
  • 29
    Nilsson E, Hultman CM, Cnattingius S, Olausson PO, Bjork C, Lichtenstein P. Schizophrenia and offspring's risk for adverse pregnancy outcomes and infant death. Br J Psychiatry 2008;193:31115.
  • 30
    Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010;341:c4024.
  • 31
    Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 2012;69:71521.
  • 32
    Ellman LM, Huttunen M, Lonnqvist J, Cannon TD. The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on obstetric complications. Schizophr Res 2007;93:22936.
  • 33
    Chwastiak LA, Rosenheck RA, Kazis LE. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics 2011;52:2306.
  • 34
    Mittal VA, Ellman LM, Cannon TD. Gene-environment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr Bull 2008;34:108394.
  • 35
    Suvisaari JM, Taxell-Lassas V, Pankakoski M, Haukka JK, Lonnqvist JK, Hakkinen LT. Obstetric complications as risk factors for schizophrenia spectrum psychoses in offspring of mothers with psychotic disorder. Schizophr Bull 2013;39:105666.
  • 36
    Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;1:CD005148.
  • 37
    Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013;2:CD007253.
  • 38
    Hauck Y, Rock D, Jackiewicz T, Jablensky A. Healthy babies for mothers with serious mental illness: a case management framework for mental health clinicians. Int J Ment Health Nurs 2008;17:38391.
  • 39
    De Hert M, Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007;33:82330.
  • 40
    L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007;68:151016.
  • 41
    Seeman MV. Clinical interventions for women with schizophrenia: pregnancy. Acta Psychiatr Scand 2013;127:1222.
  • 42
    Seeman MV, Ross R. Prescribing contraceptives for women with schizophrenia. J Psychiatr Pract 2011;17:25869.